Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for the three months ended December 31, 2025, were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [15] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control [5] - Continued enrollment and treatment progress in the Australian oncology trial, with two Hemopurifier treatments completed in the second cohort [7][9] - The R&D team is exploring the compatibility of the Hemopurifier with a simplified blood treatment system, which could enhance clinical and commercial flexibility [10] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with TrialFax and Dedicated for advertising and pre-screening [8] - The study is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve the body's ability to attack tumor cells [9] Company Strategy and Development Direction - The company is focused on advancing the Hemopurifier platform and exploring its potential as a multi-indication therapeutic [5] - The integration of the Hemopurifier with the SLAMB system could facilitate its use in oncology units and infusion centers, reducing invasiveness for patients [23][24] - The company aims to build on preclinical data in Long COVID and explore other indications related to extracellular vesicles [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of cost containment while advancing clinical trials and R&D efforts [27] - The company is currently focused on completing the Australian trial and is not planning to expand to other regions like India at this time [75][78] Other Important Information - The next earnings call for the fiscal fourth quarter, ending March 31, 2026, will coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - The follow-up period remains the same, but participants in Cohort 2 will receive two Hemopurifier treatments instead of one [19] Question: Impact of SLAMB system on treatment administration - The SLAMB system would allow for a less invasive catheter insertion, making it easier for patients and hospital staff to administer treatments [24] Question: Cost-effective approach in R&D - The company is trying to keep costs down by conducting work in-house and limiting outside lab involvement while still advancing research [27] Question: Timeline for Data Safety Monitoring Board's decision - The board is expected to provide a decision on advancing to the third cohort on the same day or the next business day after their meeting [36] Question: Need for Cohort 3 - Management believes it is important to investigate the third cohort to assess the potential benefits of three treatments compared to two [62] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company would need to conduct safety tests before using it with the Hemopurifier [47]